Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19231178rdf:typepubmed:Citationlld:pubmed
pubmed-article:19231178lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C0030193lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C0268563lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C1554184lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C1880355lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:19231178lifeskim:mentionsumls-concept:C0596431lld:lifeskim
pubmed-article:19231178pubmed:issue6lld:pubmed
pubmed-article:19231178pubmed:dateCreated2009-3-9lld:pubmed
pubmed-article:19231178pubmed:abstractTextThe purinoceptor subtypes P2X(3) and P2X(2/3) have been shown to play a pivotal role in models of various pain conditions. Identification of a potent and selective dual P2X(3)/P2X(2/3) diaminopyrimidine antagonist RO-4 prompted subsequent optimization of the template. This paper describes the SAR and optimization of the diaminopyrimidine ring and particularly the substitution of the 2-amino group. The discovery of the highly potent and drug-like dual P2X(3)/P2X(2/3) antagonist RO-51 is presented.lld:pubmed
pubmed-article:19231178pubmed:languageenglld:pubmed
pubmed-article:19231178pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19231178pubmed:citationSubsetIMlld:pubmed
pubmed-article:19231178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19231178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19231178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19231178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19231178pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19231178pubmed:statusMEDLINElld:pubmed
pubmed-article:19231178pubmed:monthMarlld:pubmed
pubmed-article:19231178pubmed:issn1464-3405lld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:FordAnthony...lld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:DillonMichael...lld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:JahangirAlamAlld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:AlamMuzaffarMlld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:LinClaraClld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:GeverJoel RJRlld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:CarterDavid...lld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:ZhaiYanshengYlld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:BoisDaisy...lld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:WagnerPaul...lld:pubmed
pubmed-article:19231178pubmed:authorpubmed-author:ZiraJeffJlld:pubmed
pubmed-article:19231178pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19231178pubmed:day15lld:pubmed
pubmed-article:19231178pubmed:volume19lld:pubmed
pubmed-article:19231178pubmed:ownerNLMlld:pubmed
pubmed-article:19231178pubmed:authorsCompleteYlld:pubmed
pubmed-article:19231178pubmed:pagination1632-5lld:pubmed
pubmed-article:19231178pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:meshHeadingpubmed-meshheading:19231178...lld:pubmed
pubmed-article:19231178pubmed:year2009lld:pubmed
pubmed-article:19231178pubmed:articleTitleIdentification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.lld:pubmed
pubmed-article:19231178pubmed:affiliationDepartment of Medicinal Chemistry, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, CA 94304, USA.lld:pubmed
pubmed-article:19231178pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:19231178lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19231178lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19231178lld:pubmed